Actively Recruiting
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-06
120
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
CONDITIONS
Official Title
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with acute myeloid leukemia (AML) excluding acute promyelocytic leukemia according to FAB and WHO 2016 criteria
- Meet criteria for refractory or relapsed AML with morphological recurrence (excluding molecular recurrence and simple extramedullary leukemia)
- No age or gender restrictions
- Signed informed consent by patient or legal guardian before study procedures
You will not qualify if you...
- Having other active malignant tumors requiring treatment
- Considered unsuitable for inclusion by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Blood Hospital
Tianjin, China, 300020
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here